compounded semaglutide shortage GLP-1 = Over FDA warns against using compounded

While semaglutide produces about 15% weight loss and Tirzepatide about 2025% in clinical trials, retatrutide has demonstrated weight loss approaching 30% in ongoing studies

Can I switch from Wegovy to retatrutide

As of 2025, retatrutide is not approved for use in the United Kingdom and is not available through the NHS or private prescription

Emerging evidence suggests that treatment with the dual GLP-1 and GIP receptor agonist, tirzepatide, might prove even more potent than a GLP-1RA alone, to ameliorate NAFLD

Some individuals lose weight relatively quickly during the first month, while others experience more gradual progress

For patients receiving tirzepatide treatment, these measures can minimize treatment disruption